Neomorph
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
5590 Morehouse Dr, San Diego, California...Website
www.neomorph.comRevenue
$20.7 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
2
About Neomorph
Neomorph is a venture-backed biotechnology company based in San Diego, California, focused on advancing the science of targeted protein degradation to develop innovative medicines against undruggable targets. The company is comprised of industry-leading experts in protein degradation and molecular glues, committed to leadership in drug discovery and clinical development. Neomorph aims to solve critical problems in human health through its proprietary technology and a pipeline of projects. Their collaborative approach emphasizes a patient-first, science-driven methodology to deliver transformative treatments.Explore more
Neomorph Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neomorph your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Neomorph launches new products
Congratulate Masked Content for being promoted to Masked Content at Neomorph
Funding: Get notified immidiatlly once Neomorph has new funding data
Neomorph, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Neomorph has recently received funding, and reach out quickly before it becomes old news!
Click to see if Neomorph had a recent Job posting/layoffs
Earning: See what the market has to say on Neomorph recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Neomorph is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Neomorph as Masked Content
Find 3 more new buyers
Compare Similar Companies to Neomorph
Compare insights from companies similar to Neomorph, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Neomorph is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Neomorph is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Neomorph.
Neomorph financials insights
Gather financial insights about Neomorph, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$109M
2026
Series B
$100M
Neomorph Tech Stack
A closer look at the technologies used by Neomorph
Most Recent Scoops
Executive Move
Robert Hugin has been appointed to serve on the Board of Directors for the organization as Chairman.
Executive Moves, Board of Directors
Open Position
Funding
Funding
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Neomorph News & Media
Neomorph to Highlight Progress in Targeted Protein Degradation Science at the American Association for Cancer Research Annual Meeting
Presentation in the New Drugs on the Horizon session to feature the development of NEO-811, a novel ARNT (HIF-1β)-targeted therapy in clear cell renal cell carcinoma (ccRCC)Biotech startup Neomorph raises $100M to crack the ‘undruggable’ protein problem with molecular glue technology
For decades, drug discovery has run into the same wall: a large share of disease-driving proteins simply couldn’t be targeted with traditional therapies. Neomorph thinks that the wall is starting to crack—and investors are betting $100 million on it. The […] The post Biotech startup Neomorph raises $100M to crack the ‘undruggable’ protein problem with molecular glue technology first appeared on Tech Startups.Neomorph Announces Closing of $100 Million Series B Financing
Financing will support the ongoing Phase 1/2 trial of NEO-811 for the treatment of locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC) and the continued advancement of the company’s broader novel molecular glue degrader pipeline Financing will support the ongoing Phase 1/2 trial of NEO-811 for the treatment of locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC) and the continued advancement of the company’s broader novel moleculNeomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platform Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platform
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neomorph
Sign Up For FreeTo access detailed company insights
Neomorph is a venture-backed biotechnology company based in San Diego, California, focused on advancing the science of targeted protein degradation to develop innovative medicines against undruggable targets. The company is comprised of industry-leading experts in protein degradation and molecular glues, committed to leadership in drug discovery an... Read More
